Pharmacologic treatments for chronic obstructive pulmonary disease: A mixed-treatment comparison meta-analysis

Pharmacotherapy

Volumn 29, Issue 8, 2009, Pages 891-905

  Baker, William L ^a,b   Baker, Erica L ^a,b   Coleman, Craig I ^a,b,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Chronic obstructive pulmonary disease; COPD; Meta analysis; Mixed treatment comparison; MTC

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; TRIAMCINOLONE;

ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; EMPHYSEMA; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; HUMANS; PATIENT COMPLIANCE; PATIENT DROPOUTS; PLACEBOS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCOPOLAMINE DERIVATIVES;

EID: 68149158110     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.8.891     Document Type: Article

References (71)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2006). Available from http://www.goldcopd.com. Accessed July 16, 2007.
2. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 2004;350:2689-2697
3. Sin DD, McAlister FA, Man SFP, Anthonisen NR. Comtemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301-2312 (Pubitemid 37430563)
4. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007;131:696-704. (Pubitemid 46446859)
5. Seemangal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;154:1418-1422 (Pubitemid 28242071)
6. Calverley PMA, Rennard SI. What have we learned from large drug treatment trials in COPD? Lancet 2007;370:774-785
7. Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of stable obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med 2007;147:639-653 (Pubitemid 351664485)
8. Calverley PMA, Anderson JA, Celli B, et al, for the TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789 (Pubitemid 46294610)
9. Wedzicha JA, Calverley PMA, Seemungal TA, Hagan G, Ansari Z, Stockley RA, for the INSPIRE Investigators. The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
10. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
11. Woodward P. BugsXLA: Bayes for the common man. J Stat Soft 2005;14:1-18.
12. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-3124 (Pubitemid 39334902)
13. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900.
14. Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med 2006;166:1269-1275 (Pubitemid 43967578)
15. Llewellyn-Jones CG, Harris TAM, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996;153:616-621 (Pubitemid 26051337)
16. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997;10:815-821 (Pubitemid 27180192)
17. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J, on behalf of the International COPD Study Group. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773-780 (Pubitemid 28112338)
18. Pauwels RA, Lohdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide In persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society study on chronic obstructive pulmonary disease. N Engl J Med 1999;340:1948-1953
19. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-965
20. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-1823 (Pubitemid 29251012)
21. Casaburi R, Briggs DD, Donohue JF, Serby CW, Monjoge SS, Witek TJ, for the U.S. Tiotropium Study Group. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest 2000;118:1294-1302
22. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-1909
23. Burge PS, Calverley PMA, Spencer S, Anderson JA, Maslen TK, on behalf of the ISOLDE Study Investigators. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303 (Pubitemid 30245717)
24. Littner MR, Ilowite JS, Tashkin DP, et al. Long-active bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1136-1142
25. van Noord JA, de Munck DRAJ, Bantje TA, Hop WCJ, Akveld MLM, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000;15:878-885 (Pubitemid 30321844)
26. 2-adrenergic agonist, salmeterol xinofoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1087-1092
27. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-224 (Pubitemid 34162820)
28. Chapman KR, Arvidsson P, Chuchalin AG, et al. The addition of salmeterol 50 μg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Can Respir J 2002;9:178-185 (Pubitemid 34863635)
29. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function in health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55.
30. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002;165:1592-1596 (Pubitemid 34693937)
31. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-1091 (Pubitemid 35178706)
32. Rossi A, Kristufek P, Levine BE, et al, for the Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058-1069 (Pubitemid 34280423)
33. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once-daily tiotropium compared with twice-daily salmeterol in patients with COPD. Thorax 2003;58:399-404. (Erratum in Thorax 2005;60:105.) (Pubitemid 36560942)
34. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919 (Pubitemid 37540641)
35. 2-Agonists (TRISTAN) Study Group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456 (Erratum in Lancet 2003;361:1660.)
36. Celli B, Halpin D, Hepburn R, Byrne N, Keating ET, Goldman M. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the breathlessness, cough, and sputum scale (BCSS). Respir Med 2003;97(suppl A):S35-43. (Pubitemid 36124429)
37. Dal Negro RW, Pamari C, Tognella S, Micheletto C. Salmeterol and fluticasone 50 mcg/250 mcg bid in combination provides better long-term control than salmeterol 50 mcg bid alone and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther 2003;16:241-246 (Pubitemid 36794391)
38. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 mcg)/salmeterol (50 mcg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124:834-843 (Pubitemid 37123298)
39. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81. (Pubitemid 36150304)
40. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnea, and exercise tolerance in COPD. Eur Respir J 2004;23:832-840 (Pubitemid 38807355)
41. Briggs DD, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005;18:397-404. (Pubitemid 41354265)
42. Campbell M, Eliraz A, Johansson G, et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med 2005;99:1511-1520 (Pubitemid 41683932)
43. Casabury R, Kukafka D, Cooper CB, Witek TJ, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;157:809-817 (Pubitemid 40775509)
44. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergics bronchodilator: a randomised trial. Ann Intern Med 2005;143:317-326 (Pubitemid 41266605)
45. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005;26:214-222 (Pubitemid 41079064)
46. Barnes NC, Qui YS, Pavord ID, et al, on behalf of the SCO30005 Study Group. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736-743
47. Beeh KM, Beier J, Buhl R, Stark-Lorenzen P, Gerken F, Metzdorf N. Efficacy of tiotropium bromide (Spiriva) in patients with chronic obstructive pulmonary disease (COPD) of different severities [in German]. Pneumologie 2006;60:341-346 (Pubitemid 44046752)
48. Dusser D, Bravo ML, Iacono P, on behalf of the MISTRAL Study Group. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006;27:547-555 (Pubitemid 43372529)
49. O'Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006;130:647-656 (Pubitemid 44423592)
50. Stockley RA, Chopra N, Rice L, on behalf of the SMS40026 Investigator Group. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006;61:122-128 (Pubitemid 43235428)
51. Verkindre C, Bart F, Aguilaniu B, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006;73:420-427 (Pubitemid 43909741)
52. Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan FP. Nebulized aformoterol in patients with COPD: a 12-week, multicenter, randomised, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther 2007;29:261-278 (Pubitemid 46671382)
53. Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care: the Spiriva usual care (SPRUCE) study. Respir Res 2007;8:45-55.
54. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-149 (Pubitemid 46115085)
55. Powrie DJ, Wilkinson TMA, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007;30:472-478
56. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomised placebo-controlled trials. Am J Med 2002;113:59-65. (Pubitemid 34775161)
57. 1 in patients with chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 2003;138:969-973
58. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005;60:992-997 (Pubitemid 41705466)
59. Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006;4:253-262 (Pubitemid 43824800)
60. 1 decline in COPD patients randomised to inhaled corticosteroids or placebo. Chest 2007;131:682-689
61. Yang IA, Fong KM, Sim EHA, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;(2):CD002991.
62. Salpeter SR, Buckley NS, Sapleter EE. Meta-analysis: anticholinergics, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006;21:1011-1019
63. Stockley RA, Whitehead PJ, Williams MK. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis. Respir Res 2006;7:147-157
64. Barr RG, Bourbeau J, Camargo CA, Ram FSF. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61:854-862 (Pubitemid 44570305)
65. Calverley PMA, Spence S, Willits L, Burge PS, Jones PW, on behalf of the ISOLDE Study Group. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003;124:1350-1356 (Pubitemid 37290045)
66. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-207 (Pubitemid 46111014)
67. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2008;289:2534-2544 (Pubitemid 37430155)
68. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769-1781
69. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparisons for estimated efficacy of competing interventions: empirical evidence from published meta-analyses [online exclusive article]. BMJ 2003;326:472. Available from http://www.bmj.com/cgi/content/full/326/7387/472?view=long&pmid= 12609941. (Pubitemid 36269627)
70. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117:S398-401. (Pubitemid 30314474)
71. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:842-846